Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosfomycin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Meitheal Pharmaceuticals Expands Portfolio with Acquisition of CONTEPO™ from Nabriva
Details : Meitheal has acquired the North American rights to CONTEPO (fosfomycin) from Nabriva. CONTEPO is a novel, intravenous, broad-spectrum antibiotic used for the treatment of urinary tract infections.
Product Name : Contepo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 18, 2024
Lead Product(s) : Fosfomycin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XENLETA (lefamulin) is first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required...
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xenleta (lefamulin) is a novel, first-in-class, IV and oral pleuromutilin antimicrobial agent that has been demonstrated to be highly potent against S. aureus, including MRSA and strains obtained from patients with CF.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XENLETA has the potential to provide a well-tolerated oral and intravenous anti-MRSA treatment option with a novel mechanism for this difficult to treat patient population. We look forward to sharing the results of this study with the medical community.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Erkim
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Er-Kim gains exclusive rights to distribute XENLETA (lefamulin) in the following countries: Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 18, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Erkim
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the initial term of the agreement, Nabriva was solely responsible for marketing, sales, and distribution of SIVEXTRO (Tedizolid Phosphate) in the United States through December 31, 2023. The amendment extends the agreement to December 31, 2026.
Product Name : Sivextro
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia
Details : Sumitomo filed NDA to market oral and IV formulations of lefamulin,first systemic pleuromutilin antibiotic for the treatment of community-acquired pneumonia in adults in mainland China.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2021
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Lefamulin for M. Genitalium Treatment Failures
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2021
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nabriva Therapeutics to Present Data at IDWeek 2021
Details : XENLETA® (lefamulin) is first-in-class pleuromutilin antibiotic for treatment of community-acquired bacterial pneumonia (CABP). It's in vitro activity of lefamulin against Staphylococcus aureus isolated from lower respiratory tract of children with cyst...
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable